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Å          angstrom 
Akt       acutely transforming retrovirus AKT8 in rodent T cell lymphoma
CDM    cell-derived matrix 
Col I     collagen type I 
ERK     extracellular signal–regulated kinase
ExAC   Exome Aggregation Consortium 
FBS     fetal bovine serum
FN       fibronectin
FXIII-A Factor XIII subunit A
GAPDH glyceraldehyde-3-phosphate dehydrogenase
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GFP      green fluorescent protein
GST      glutathione S-Transferase 
GTP      guanosine triphosphate
HEK      human embryonic kidney
HET     heterozygous
HRP     horseradish peroxidase
ILDT   Isoleucine-Leucine-Aspartate-Threonine 
IRES    internal ribosome entry site
MAPK mitogen-activated protein kinase
NHDF    normal human dermal fibroblast
PBS     phosphate buffered saline
PDGF  platelet-derived growth factor
PDGFR platelet-derived growth factor receptor 
Pl3K     phosphatidylinositol 3 kinase 
TBS    Tris buffered saline
WES    whole exome sequencing 
WT      wild type
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Abstract 
Dermatofibromas are common benign skin lesions, the etiology of which is poorly understood. 
We identified two unrelated pedigrees in which there was autosomal dominant transmission of 
multiple dermatofibromas. Whole exome sequencing revealed a rare shared heterozygous 
missense variant in F13A1 gene encoding factor XIII subunit A, a transglutaminase involved 
in hemostasis, wound healing, tumor growth, and apoptosis. The variant (p.Lys679Met) has an 
allele frequency of 0.0002 and is predicted to be a damaging mutation. Recombinant human 
Lys679Met FXIII-A demonstrated reduced fibrin crosslinking activity in vitro. Of note, 
treatment of fibroblasts with media containing Lys679Met FXIII-A led to enhanced adhesion, 
proliferation and type I collagen synthesis. Immunostaining revealed co-localization between 
FXIII-A and 41 integrins, more prominently for Lys679Met FXIII-A than wild-type. In 
addition, both the 41 inhibitors and the mutation of the FXIII-A Isoleucine-Leucine-
Aspartate-Threonine (ILDT) motif prevented Lys679Met FXIII-A-dependent proliferation and 
collagen synthesis of fibroblasts. Our data suggest that the Lys679Met mutation may leads to 
a conformational change in the FXIII-A protein that enhances 4-integrin binding and provide 
insight into an unexpected role for FXIII-A in the pathobiology of familial dermatofibroma.
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INTRODUCTION 
Dermatofibromas are common benign fibro-histiocytic tumors (Jakobiec et al., 2014; 2017). 
Typically, dermatofibromas present as solitary 0.5-1cm pink, red, tan or flesh-colored lumps 
with an overlying dimple-like depression (Zelger and Zelger, 1998). Sometimes multiple 
dermatofibromas may occur, occasionally in families, but more often in individuals with 
underlying immunologic or other clinical abnormalities (Beatrous et al., 2017). The most 
common site for dermatofibromas is the lower legs, with usual onset during early adulthood. 
The cause of dermatofibromas is not known although dermatologists may suggest they occur 
following insect bites in susceptible individuals, or possibly following trauma (Kluger et al., 
2008; Myers and Fillman 2019).
Histologically, in dermatofibromas (single or multiple) there are interlacing fascicles 
of slender spindle-shaped cells within a loose collagenous, or occasionally myxoid, stroma. Of 
note, hemosiderin is frequently present. Immunohistochemically, almost all dermatofibromas 
are FXIII-A (factor XIIIA antigen)-positive (Altman et al., 1993), and indeed immunostaining 
for FXIII-A is frequently used in the tissue diagnosis of dermatofibromas (Cerio et al., 1988; 
1989). 
In this study, we performed whole exome sequencing (WES) to identify the causative 
mutation in two seemingly unrelated pedigrees with autosomal dominant familial multiple 
dermatofibromas. Intriguingly, we identified the same mutation in F13A1 encoding the A-
subunit of factor XIII (FXIII-A) in both families. FXIII is a member of transglutaminase family 
which crosslinks various proteins involved in hemostasis, wound healing, tumor growth, and 
apoptosis (Muszbek et al., 2011). During wound healing, FXIII modulates fibroblast and 
macrophage biology and contributes to angiogenesis (Bagoly et al., 2012, Duval et al., 2016, 
Muszbek et al., 2011). While plasma FXIII is composed of two catalytic A subunits and two 
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non-catalytic carrier B units generating a A2B2 heterotetramer (Komaromi et al., 2011), cellular 
FXIII (found, for example, in platelets and megakaryocytes) is formed solely of A subunits 
organized in an A2 homodimer. The mutation we identified in this study affects the A subunit, 
i.e. it impacts on both the plasma and tissue/cellular FXIII forms (PMID: 30489000, PMID: 
5096097). We provide evidence that the FXIII-A mutation leads to enhanced proliferation and 
collagen synthesis in fibroblasts, potentially through promoting binding of exogenous FXIII-
A to integrins. Our study therefore provides insight into an important role for FXIII-A in the 
etiology and pathobiology of some dermatofibromas.
RESULTS
Clinical features and histology 
We examined seven affected individuals from two unrelated families with multiple 
dermatofibromas inherited in an autosomal dominant pattern (Figure 1a). Three affected 
individuals were from the Ukraine (Family 1) and four affected were from the USA (Family 
2). Both families were Jewish (Ashkenazi). Some clinicopathologic details of Family 2 have 
been published previously (Samlaska and Bennion, 2002). All subjects presented with multiple 
lesions of erythematous papules over extremities (Figure 1b; illustrations from Family 1 and 
2) with histopathologic findings of dermatofibromas (Figure 1c; Family 1, II-2). No extra-
cutaneous manifestations were reported.
All individuals with multiple dermatofibromas are heterozygous for the mutation 
c.2036A>T (Lys679Met) in F13A1 
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We undertook WES in six affected subjects from the Ukraine and US families and two 
unaffected individuals from the US family. Candidate mutations were prioritized by filtering 
for variants with a frequency of less than 0.01% in public repositories such as the 1000 
Genomes Project, Exome Aggregation Consortium (ExAC) and an in-house database 
(Supplementary Table S1, S2). Using these criteria, a missense variant in F13A1 encoding 
Factor XIII subunit A (c.2036A>T; rs201302247) was the only variant present in all affected 
individuals in both families. Subsequent Sanger sequencing confirmed the mutation in affected 
individuals (Supplementary Figure S1) and co-segregated with disease status in all relatives 
who provided DNA samples. This variant was rare in the population (less than 0.0207% 
frequency) and resulted in an amino acid change from lysine to methionine at position 679 
(position 678 in the mature protein) with an in silico prediction that the mutation is damaging 
(Polyphen-2 = 1; Mutation taster = 1; CADD = 25.5; DANN = 0.993). 
c.2036A>T in F13A1 is a rare allele found most commonly in Ashkenazi Jews
To investigate the possibility that c.2036A>T was inherited from a common ancestor, we 
performed a haplotype analysis to study the mutant alleles from affected individuals using four 
highly polymorphic single nucleotides polymorphism markers based on the exome data 
(Supplementary Figure S2). The data showed identical haplotypes among affected individuals 
(in contrast to the unaffected individuals) indicating that c.2036A>T probably occurred on the 
same ancestral allele. Of note, the allele frequency of rs201302247 in Ashkenazi Jews (0.397%) 
is almost 20 times higher than that in the general population (Genome Aggregation Database; 
https://gnomad.broadinstitute.org/variant/6-6152055-T-A). The incidence of familial multiple 
dermatofibromas is not known (in any population) but our data indicate that, although rare and 
perhaps underreported, it may be substantially higher in Ashkenazi Jews.
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Mutations in F13A1 are not detectable in sporadic dermatofibromas
To explore whether mutations in F13A1 might also be present in the more common sporadic 
dermatofibromas, we undertook Sanger sequencing of the coding and promoter regions of 
F13A1 using DNA extracted from paraffin-embedded tissue of 22 sporadic single 
dermatofibromas from unrelated individuals; no potentially deleterious variants were identified 
(Supplementary Methods and Results, and Tables S3-S6).
The mutation Lys679Met in FXIII-A results in reduced crosslinking activity 
To assess the activity of the Lys679Met mutant FXIII-A protein, we generated Glutathione S-
Transferase (GST)-fusions of wild-type (WT) or Lys679Met FXIII-A (see Supplementary 
Table S7 for site directed mutagenesis details), purified recombinant proteins (Figure 2a) and 
performed pentylamine incorporation into casein assays. We found that the Lys679Met FXIII-
A mutation led to reduced crosslinking at 30 min by 50% compared to WT protein (Figure 2b, 
c). To find possible clues for the altered catalytic activity we looked at the available structural 
information. Factor XIII-A is composed of five major structural regions: an N-terminal 
activation peptide (residues 1-38), a β-sandwich domain (residues 39-184), a catalytic domain 
(185-516), and two β-barrel domains (517-628 and 629-732) that in the inactive FXIII-A 
zymogen are arranged in a dimer (Figure 2d) (Yee et al., 1994; Weiss et al., 1998). Residue 
Lys679 is solvent exposed and maps on a β-strand of the second β-barrel domain. In the inactive 
enzyme, access to active site is occluded by an intramolecular interaction within the first β-
barrel domain which, in turn, is stabilized by the N-terminal peptide of the second FXIII-A 
molecule. Enzyme activation involves thrombin cleavage of the activation peptide in the 
presence of Ca2+ ions, and calcium binding results in dimer destabilization and a large structural 
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rearrangement involving a swinging movement of both β-barrel domains (Figure 2e). This 
leads to an active FXIII-A monomer in which the active site is accessible (Stieler et al., 2013). 
In the active conformation observed by crystallography, Lys679 is located away from the active 
site (more than 63 angstroms (Å)) ruling out a direct effect of the Lys to Met mutation on the 
catalytic machinery. This mutation could alternatively play a role in the activation mechanism. 
The first five amino acids of the activation peptide are not visible in the structure of the inactive 
FXIII-A dimer and Lys679 is approximately 22 Å away from the first ordered residue (Arg 6). 
Thus, based on distance considerations, stabilization of the flexible N-terminal peptide by the 
Lys679Met residue would require some structural rearrangements. We should also point out 
that in our pentylamine incorporation assay we employed Prescission-cleaved recombinant 
FXIII-A. Therefore, we cannot exclude that the slightly longer N-terminus resulting from the 
cloning strategy fortuitously might be stabilized by the Lys679Met mutation more than occurs 
in vivo wherein the Ser2 is expected to be acetylated following cleavage of the first methionine 
(GPMSETSR…. instead of Ac-SETSR….). More detailed biochemical experiments need to be 
performed to validate the observed change in catalytic activity and understand its possible 
molecular basis.
The mutation Lys679Met in FXIII-A promotes proliferation and collagen production in 
human dermal fibroblasts
Proliferation assays were performed to determine whether FXIII-A contributes to fibroblast 
cell proliferation in dermatofibromas. To expose fibroblasts to FXIII-A, we expressed WT or 
Lys679Met FXIII-A coupled to GFP by means of an IRES in human embryonic kidney 
(HEK293) cells and collected secreted protein in the conditioned media. Both WT and 
Lys679Met constructs yielded similar levels of secreted protein (Figure 3a, inset blot). 
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Treatment of fibroblasts with this media demonstrated that incubation with WT FXIII-A led to 
higher proliferation rates after 48h, whereas Lys679Met FXIII-A led to significantly higher 
proliferation rates at both 24 and 48h post-incubation (Figure 3a).  To determine whether 
treatment with FXIII-A also altered pro-fibrotic matrix secretion by fibroblasts, collagen I and 
fibronectin levels were assessed in whole cell lysates. Western blots revealed a significant 
increase in collagen synthesis in Lys679Met FXIII-A treated cells but not those treated with 
WT FXIII-A media, compared to controls (Figure 3b), whereas no change in levels of 
fibronectin were detected between samples (Supplementary Figure S3a).  Quantitative PCR 
analysis further demonstrated upregulation of collagen I mRNA levels in Lys679Met FXIII-A 
treated cells compared to WT (Figure 3c). To further analyze native ECM deposition by cells, 
fibroblasts were grown for 14 days on coverslips to generate cell-derived matrix (CDM) in the 
presence or absence of FXIII-A. Imaging of the resulting CDM preparations revealed an 
apparent increase in disorganized collagen production in cells treated with Lys679Met FXIII-
A compared to WT (Figure 3d). These combined data suggest that FXIII-A can promote 
fibroproliferative responses in fibroblasts and that the identified Lys679Met mutation enhances 
this property of FXIII-A.
Lys679Met FXIII-A shows higher association with α4β1 integrins on fibroblasts 
Our data demonstrated that, in contrast to lower activity as a coagulation factor, Lys679Met 
FXIII-A exhibited more activity in terms of a fibroproliferation.  Previous data have suggested 
that FXIII-A binds to α4β1 integrin to elicit some cellular activities (Isobe et al., 1999). To 
explore this possibility, we performed early adhesion assays to collagen I substrates of 
fibroblasts pre-treated with WT or Lys679Met FXIII-A. Data revealed a significant increase in 
adhesion of cells treated with Lys679Met FXIII-A compared to WT or control samples (Figure 
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3e), suggesting enhanced integrin activation in these cells. Given that α4β1 integrin is a 
fibronectin receptor and does not directly bind to collagen I, other matrix receptors e.g. α1β1, 
α2β1 integrin may be involved in the binding. 
To investigate whether FXIII-A binds to specific sites on the cell surface, the 
localization patterns of FXIII-A, α4 and active β1 integrins were analyzed in FXIII-A-treated 
fibroblasts by confocal microscopy. Images and subsequent analysis revealed that active β1 
integrins co-localized with WT FXIII-A and this was significantly increased for Lys679Met 
FXIII-A (Figure 4a, b). Moreover, levels of active β1 integrins were significantly higher in 
Lys679Met FXIII-A treated cells compared to WT or untreated cells (Figure 4c), further 
supporting the notion that mutant FXIII-A can activate integrin receptors at the surface of 
fibroblasts. Similarly, α4 integrins showed a significant increase in co-localization between 
with Lys679Met FXIII-A compared to WT (Figure 4d, e), indicating that mutant FXIII-A either 
binds with higher specificity to α4 integrin, or that the protein remains at these sites for longer 
after binding. No significant difference in levels of total α4 integrin protein were observed 
between WT and Lys679Met FXIII-A treated cells, (Supplementary Figure S3c, d) suggesting 
that FXIII-A exerts effects at the level of integrin localization in fibroblasts. This observation 
suggests FXIII-A associates with integrins and results in increased receptor activation.  
To further investigate whether FXIII-A may co-operate with α4β1 to elicit phenotypic 
effects, cells were pre-treated with α4β1-specific inhibitors (BIO1211, BOP and TCS2134) 
prior to treatment with FXIII-A. Confocal imaging of α4β1 integrins revealed a visible 
reduction in the levels of both WT and Lys679Met FXIII-A associated with the plasma 
membrane in cells treated with BIO1211, suggesting active α4β1 is required for FXIII-A 
binding to the plasma membrane (Figure 5a). Further analysis demonstrated that all three 
integrin inhibitors suppressed the Lys679Met FXIII-A-dependent increase in collagen 
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synthesis (Figure 5b) and proliferation (Figure 5c). These observations suggest that FXIII-A 
requires α4 integrin to associate with the membrane and promote fibroproliferative responses.
FXIII-A has previously been suggested to associate with integrins through the 
isoleucine-leucine-aspartate-threonine ‘ILDT’ amino acid motif located on the catalytic 
domain (Isobe et al., 1999). To test this hypothesis, site-directed mutagenesis was performed 
to mutate the ILDT motif to AAAA in FXIII-A and define the potential role of this site in 
regulating fibro-proliferative phenotypes. We found that mutation of ILDT to AAAA resulted 
in inhibition of the FXIII-A-induced increase in both collagen production and proliferation 
(Figure 5d, e). These data support the notion that FXIII-A can bind to α4 through the ILDT 
motif and that this region may co-operate with the residues around Lys679 to promote α4 
association.
FXIII-A regulates mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 
kinase (PI3K) activation
To further investigate potential mechanisms by which FXIII-A promotes cell proliferation and 
collagen synthesis, we analyzed activation of a range of different signaling pathways in cells 
treated with WT or Lys679Met FXIII-A. Tissue transglutaminase has been reported to promote 
platelet-derived growth factor receptor (PDGFR)-integrin association, and we therefore 
hypothesized that FXIII-A binding may enhance activation of this pathway (Zemskov et al., 
2009). Western blotting analysis of cells treated with WT or Lys679Met FXIII-A revealed no 
significant increase in PDGFR activity (as judged by pTyr-751 reactivity, Figure 6a). There 
were also no detectable changes in activity of the small guanosine triphosphatase (GTPase) 
RhoA, that is known to be activated downstream of integrins and can contribute to collagen 
synthesis (Supplementary Figure S3e). However, further analysis of other downstream 
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signaling targets (Akt, ERK1/2, p38alpha) revealed that pAkt and pERK both showed 
significantly increased activation levels in cells following 1h of treatment with both WT and 
Lys679Met FXIII-A (Figure 6a, b, c). Taken together, these data suggest that FXIII-A can 
promote activation of Akt and MAPK pathways, which may potentially increase cell 
proliferation (Figure 6d). 
DISCUSSION
Dermatofibroma is a common benign fibro-histiocytic skin tumor but little is known about its 
pathogenesis (Hsi and Nickoloff, 1996). Typically, dermatofibromas are thought to be induced 
by trauma, particularly following insect bites. Here, we investigated two unrelated pedigrees 
with autosomal dominant familial multiple dermatofibromas and identified a heterozygous 
missense mutation in FXIII-A. On one level this is a surprising finding given that FXIII-A 
antibodies have been used for the last 40 years for the immunohistochemical diagnosis of 
dermatofibromas (Cerio et al., 1988).  Nevertheless, we also demonstrated that the mutant 
FXIII-A protein has a functional impact with reduced crosslinking activity but increased 
fibroblast cell proliferation and adhesion and type I collagen synthesis. Thus, FXIII-A is not 
only a useful immunohistochemical marker for dermatofibromas but it is also directly 
implicated in the molecular genetics of families with multiple dermatofibromas, at least in this 
study.
FXIII-A is found mainly in macrophages and other cell types including fibroblast-like 
mesenchymal cells and is expressed in many fibrovascular tumors (Cerio et al., 1989, Nemeth 
and Penneys, 1989). Indeed, in dermatofibromas, aside from fibroblasts, the main cellular 
component comprises cells of monocyte/macrophage lineage and it is these cells that mainly 
express FXIII-A.  In addition, FXIII-A is also present in platelet granules (Muszbek et al., 
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2011). Our working hypothesis, therefore, is that an insect bite or direct trauma may promote 
a bleed (hemosiderin is common in dermatofibromas, Figure 1c lower image). This bleeding 
may be enhanced by the presence of Lys679Met FXIII-A which shows reducing clot 
stabilization function (but no clinical bleeding abnormality). The small bleed then triggers 
platelet plug formation, platelet granule degradation and release of FXIII-A that then impacts 
on fibroblast cell biology and collagen production. Still to be explored and currently 
unexplained, however, is the role of mutant FXIII-A in monocyte/macrophages. 
Previously, autosomal recessive mutations in FXIII-A (mostly A-subunit, rarely B) 
have been identified in very rare bleeding disorders (incidence ~1 in 5 million), sometimes 
with wound healing abnormalities (Karimi et al., 2009), but no pathogenic autosomal dominant 
mutations have been previously described. The mutation Lys679Met is not a novel variant but 
is present in the general population with low frequency (risk allele frequency 0.0207%; 
rs201302247); the allele is more common among Ashkenazi Jews (Genome Aggregation 
Database). Our expectation is that other individuals with this heterozygous missense mutation 
may also have multiple dermatofibromas, although this remains to be proven. Regarding 
sporadic, non-familial dermatofibromas, we did not find any evidence for F13A1 genetic 
variants and therefore the role that FXIII-A may play (or not) in such lesions awaits further 
study. 
Previous reports have suggested that recessive mutations within the β-barrel 1 and β- 
barrel 2 domains of FXIII-A can affect the regions of the protein that regulate conformational 
changes during activation (Thomas et al., 2016). Our analysis suggests that the Lys679Met 
mutation is more likely to have an impact on the activation step rather than a direct effect on 
the catalytic machinery. The exact molecular details of how this might occur are not yet clear. 
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Two key phenotypes of dermatofibroma are fibroblast proliferation and collagen 
production. In contrast to reduced coagulation function, the mutation Lys679Met clearly 
enhances both pro-fibrotic and proliferative effects, as evidenced by the proliferation data and 
type I collagen qPCR, western blots and cell-derived matrix production.  Our data also suggest 
that FXIII-A associates with α4β1integrins at the plasma membrane to elicit these phenotypic 
effects and that this is mediated via the ILDT motif in FXIII-A. Lys679Met FXIII-A may bind 
with a higher affinity or for a greater length of time to α4 integrins. However, biochemical in 
vitro studies to assess direct binding would be required to validate this hypothesis. 
We further explored the link between α4 integrin activation and proliferation and 
collagen synthesis. Published evidence suggests that upon activation, integrins can activate 
PDGFR or LRP-6 (Muramatsu et al., 2004, Ren et al., 2013, Zemskov et al., 2009) although 
we did not observe any activation in these receptors. We also did not observe changes to the 
activity of RhoA upon FXIII-A addition to fibroblasts. We demonstrated significant increases 
in pERK1/2 and pAkt upon FXIII-A binding, which are key downstream targets in the 
RAS/RAF/MEK/ERK and the PI3K/Akt signaling pathways, but there were no differences 
between WT and Lys679Met (De Luca et al., 2012). For now, we conclude that the proposed 
enhanced action of Lys679Met FXIII-A on α4 integrin could initiate different signaling 
cascades which remain to be determined (Figure 6d). 
In summary, our study provides insight into the genetic and cellular basis of a subset of 
familial dermatofibromas and highlight an extended role for FXIII-A in their pathobiology.
MATERIALS AND METHODS
Whole Exome Sequencing (WES) and Sanger Sequencing 
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Following informed consent from the patients and ethics committee approval, WES was 
performed using DNA from available probands and their family members by the Illumina 
HiSeq2500 system (Illumina, San Diego, CA). The Exome capture kit (Agilent SureSelect 
Human All Exon 50 Mb kit, Santa Clara, CA) was used to prepare DNA libraries from 3 µg of 
DNA. First, the Adapted Focused Acoustic technology (Covaris, Woburn, MA) was used to 
shear genomic DNA to yield a mean of 150bp fragment size. The fragment ends were then 
repaired, ligated with sequencing adaptors and hybridized against biotinylated 120bp RNA 
probes (Agilent) targeting protein-coding genomic regions for 24 hours. Targeted regions were 
selected for with magnetic streptavidin-coated beads while unbound DNA was washed off. The 
exome-enriched DNA pool was next eluted, amplified with low-cycle PCR, multiplexed (4 
samples on each lane) and sequenced with 100bp paired-end reads. Reads were aligned to the 
GRCh37/hg19 reference genome using Novoalign (Novocraft Technologies, Selangor, 
Malaysia). The Bedtools package and custom scripts were used to calculate the depth of 
sequence coverage (Quinlan and Hall, 2010). The SAMtools software was used for variant 
calling and quality filtering (Li et al., 2009). Variants were then annotated with multiple passes 
through the ANNOVAR software package (Wang et al., 2010). PCR and Sanger sequencing 
were performed to validate the segregation of the mutation with phenotypes according to 
standard protocol using primers for F13A1 exon14 (Supplementary Tables S5).
Purification of FXIII-A- GST fusion proteins for functional analysis
pGEX-FXIII-A, an expression vector encoding an N-terminal GST-FXIII-A fusion protein, 
was generated as previously described (Smith et al., 2011). Lys679Met FXIII-A variant was 
generated by site-directed mutagenesis using the listed primers (Supplementary Table S7) with 
QuickChange II Kit (Agilent Technologies; Stockport, UK). Successful mutagenesis was 
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verified by DNA sequencing. Both FXIII-A plasmids were then transformed into XL10-Gold® 
Ultra-competent E. Coli (Agilent Technologies, Wokingham, UK). FXIII-A2 Expression and 
purification were performed as previously described (Duval et al., 2016). 
FXIII-A activity analysis by Pentylamine Incorporation
Measurement of FXIII activity was performed using a modified 5-(biotinamido) pentylamine 
incorporation assay.  Nunc-Immuno- 96 Micro-Well plates were coated with 100µl of 10µg/ml 
N, N-dimethylated casein overnight at 4°C, then blocked with 300µl 1% BSA in Tris buffer 
saline (TBS) for 90min at 37°C. Plates were then washed with 4x 300µl TBS and 10µl of 
samples (WT or Lys679Met rhFXIII-A2 or murine plasma) were added to the wells in triplicate. 
90µl of activation mix (111µM dithiothreitol, 0.3µM biotinylated pentylamine, 11mM CaCl2, 
2.2U/ml thrombin) was added and the reactions were stopped at 0, 20, 40, 60, 80, 100, 120 min 
by adding 200µl of 200mM EDTA. Plates were washed with 4x 300µl 0.1% [v/v] Tween20 in 
TBS, and 100µl of 2µg/ml of streptavidin in 1% [w/v] BSA (in TBS-Tween) were added for 
60min at 37°C. Following washes with 4x 300µl TBS-Tween, 100µl of 1mg/ml phosphatase 
substrate (in 1M diethanolamine) were added, and the reaction was stopped by adding 100µl 
of 4M NaOH. Absorbency was measured at 405nm, using a SpectraMax 190 absorbance 
microtiter plate reader (Molecular Devices, Wokingham, UK). The rate of pentylamine 
incorporation over time was then used as an indicator of PreScission-cleaved FXIII activity. 
Experiments were performed in triplicate.
Normal human dermal fibroblast (NHDF) and HEK293 cell culture
NHDFs (Cellworks, Buckingham, UK)  up to passage number 10 and HEK293 cell (ATCC; 
Middlesex, UK) were cultured in DMEM in high glucose (4.5g/L), 10 % (v/v) fetal bovine 
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serum (FBS), 50µg/ml penicillin and 2mM L-glutamine in a humidified incubator at 37°C with 
5%CO2. Cells were tested for Mycoplasma infection with Mycoalert™ Mycoplasma Detection 
Kit (Lonza, Slough, UK).
Plasmids constructs, site directed mutagenesis and FXIII-A expression in HEK293 cell 
line
Site-directed mutagenesis was performed on the mammalian expression vector pIRES2-EGFP 
expression vector containing the cDNA FXIII-A (a kind gift from Consuelo González-
Manchón, Madrid; Jayo et al., 2009) according to the QuikChange Lightning Site-Directed 
Mutagenesis Kit protocol (Agilent Technologies) using primers (Supplementary Table S7). 
Transient transfection was performed using Lipofectamine 3000 on HEK293 Cell line. 
Transfected cells were grown in 2% FBS containing media for 48 hours before collecting the 
conditioned media for experiments. FXIII-A expression level was verified by Western blotting.
Proliferation, adhesion assays and cell-derived matrix (CDM) preparation 
Fibroblasts were plated in media containing 2% serum a day before the experiment. Cells then 
were treated with conditioned media containing either WT or Lys679Met FXIII-A for 24 and 
48 hours for proliferation assay. Collagen type I solution from rat tail (Sigma-Aldrich) at a 
concentration of 50µg/ml was used to coat a plate for adhesion assays.  For CDM preparation, 
cells were grown on 0.2% crosslinked gelatin-coated coverslips for 14 days before cell 
denudation, as previously described (Kaukonen et al., 2017). Cells and matrices were then fixed 
for 10 minutes at room temperature with 4% final concentration of paraformaldehyde.  Cells 
were permeabilized with 0.1% Triton-X100 in phosphate buffered saline (PBS) solution for 10 
minutes followed by 1-hour incubation with 3% BSA in PBS solution containing 1:400 
Page 29 of 59 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
 O
nly
20
phalloidin-AlexaFluor488 and 1:1000 DAPI. The images of cells were acquired by tile-scans 
of each well using EVOSTM FL Auto 2 Imaging System (ThermoFisher, Waltham, MA) with 
a 10x objective lens. The number of cells in each well was measured by automated nuclei 
counting using ImageJ. 
Reverse Transcription PCR 
Fibroblasts were treated with WT and Lys679Met FXIII-A for 48 hours. Total RNA was 
extracted using RNeasy Micro Kit (Qiagen). The quality of RNA was analyzed by the 
Nanodrop spectrophotometer (ThermoFisher). Reverse Transcription was performed using 
High-Capacity cDNA Reverse Transcription Kit according to the manufacturer’s protocol. 
Gene expression was assessed by real-time PCR by using TagMan® Gene Expression Assays 
for Col1a1 Mm00801666_g1 (ThermoFisher). Transcript levels were normalized to GAPDH 
expression, measured with Applied Biosystems (Foster City, CA) TaqMan probes.                                                                                                                                                                                     
Western blot analysis 
Whole-cell lysates of fibroblasts were collected after treatment with FXIII-A conditioned 
media using RIPA buffer with protease inhibitor cocktail set I (Calbiochem, San Diego, CA). 
Each sample was resuspended in NuPAGE™ LDS Sample Buffer (Invitrogen™), boiled at 
100°C for 5 minutes and run on NuPAGE™ 4-12% Bis-Tris Protein Gels (Invitrogen™). 
Resolved proteins were transferred and blotted onto nitrocellulose membrane. Primary and 
secondary antibodies are listed (Supplementary Table S8).
Immunofluorescence and confocal microscopy
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Fibroblasts on coverslips were treated with WT and Lys679Met FXIII-A over variable time 
points, then washed and fixed with 4% paraformaldehyde in PBS before 10-minute 
permeabilization with 0.1% Triton-X100, followed by blocking with 5% BSA in PBS for 30 
minutes. Cells were labelled with antibodies (Supplementary Table S8) at 4°C overnight and 
then stained with secondary antibodies (Supplementary Table S8), phalloidin-AlexaFluor568 
and DAPI. Cells were imaged with 60x objective using Nikon A1R inverted confocal 
microscope. Images were exported from Nikon Elements software for further analysis in 
ImageJ software using intensity functions of the co-localization analysis plugin JaCoP.
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Figure legends:
Figure 1: Clinicopathologic and molecular basis of familial multiple dermatofibromas. 
(a)  Pedigrees of the two families showing all affected individuals with the F13A1 mutation 
c.2036A>T (Lys679Met). (b) Multiple dermatofibromas in Family 1 individual II-2 (left) and 
Family 2 individuals II-3 (right). (c) Histopathologic features of an excised dermatofibromas 
from an individual II-2 in Family 1 showing proliferation of fibro-histiocytic cells within the 
dermis with an overlying Grenz zone (left image; hematoxylin and eosin, ×4; scale bar 500μm 
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). There is collagen entrapment at the periphery of the lesion as well as presence of hemosiderin 
pigment (right image; hematoxylin and eosin, ×10; scale bar 200μm).  
    
Figure 2: Mutation Lys679Met in FXIII-A leads to reduced protein activity (a) SDS PAGE 
gel showing purity and levels of WT and Lys679Met FXIII-A purified recombinant proteins 
used in the assay. (b) Graph showing rate of pentylamine incorporation over time in 
preparations containing WT or Lys679Met mutant protein. (c) Percentage biotin incorporation 
as an estimation of FXIII activity. The data display means +/- SD for three experiments. *** = 
p=0.0007. (d) Cartoon representation of the inactive FXIII-A dimer (PDB code 1F13). For one 
FXIII-A molecule distinct structural regions are labeled and highlighted using different colors. 
The second FXIII-A molecule is shown in grey. Residue Lys679 is shown as stick 
representation in black. Residues of the catalytic triad are shown in orange. Lys679 is located 
~22 Å away from the first ordered residue of the N-terminal activation peptide. (e) Cartoon 
representation of Ca2+-activated FXIII-A monomer (PDB code 4KTY) shown in the same 
orientation as in (d) Color-codes for the distinct structural regions are the same as in (d). The 
inhibitor bound in the active site is shown in cyan. Calcium ions are shown as grey spheres. 
Residue Lys679 is shown as stick representation in black. Ca2+-induced activation elicits a 
large swinging movement of the β-barrel domains. In this conformation Lys679 is located ~63 
Å away from the active site.
Figure 3: Mutation Lys679Met in FXIII-A leads to increased fibroblast proliferation, 
collagen production and changes in extracellular matrix organization. (a) Graph shows 
that NHDF proliferation is increased for Lys679Met FXIII-A compared to WT FXIII-A at both 
24 and 48 hours. (b) Collagen I western blot and (c) qPCR show that Lys679Met FXIII-A 
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promotes more collagen I production after 48 hours compared to WT FXIII-A. (d) Images of 
CDM produced by cells showing those treated with Lys679Met FXIII-A express more collagen 
made of thickened fibers compared to WT FXIII-A (scale bars 10um). (e) Adhesion assay 
showing number of cells adhering to collagen I-coated plate at 1 hour is greater for Lys679Met 
FXIII-A compared to WT FXIII-A. The data indicate means +/- SD for three experiments* = 
p<0.05 * * = p<0.01 vs control, *** = p<0.001 vs control. All experiments were done in 
triplicate (n=3). C, W and M indicates control, wild type or mutant, respectively.
Figure 4: Co-localization of α4, β1 and FXIII-A on the cell surface suggests FXIII-A binds 
to α4β1 integrin Immunofluorescence staining and confocal microscopy of fixed, 
permeabilized NHDFs on coverslips after treatment with WT FXIII-A or Lys679Met FXIII-A 
for 2 hours before fixation. (a) Images show co-localization of active β1integrin and FXIII-A 
after treatment with either WT or mutant FXIII-A (scale bars 10um). (b) Manders overlap co-
efficient analysis showing percentage overlap between FXIII-A and active β1integrin is greater 
for Lys679Met FXIII-A. (c) Level of Active β1 integrin intensity per cell is greater for 
Lys679Met FXIII-A.  (d) Images show co-localization of α4 integrin and FXIII-A which is 
greater for Lys679Met FXIII-A compared to WT FXIII-A (scale bars 10um).  (e) Manders 
overlap co-efficient analysis showing percentage overlap between FXIII-A and integrin is 
greater for Lys679Met FXIII-A. All experiments were done in triplicate. The data represent 
means +/- SD for three experiments* = p<0.05 vs control ** = p<0.01 vs control *** = p<0.001 
vs control 
Figure 5: FXIII-A associates with α4β1integrin via the ILDT motif in FXIII-A. (a) NHDFs 
on coverslips were pre-treated with either DMSO (control) or BIO1211 (41 integrin 
inhibitor) for 2 hours and then WT FXIII-A, Lys679Met FXIII-A and control conditioned 
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media was added for 1 hour. Confocal images show that BIO1211 induces internalization of 
α4 integrin (small green dots); there is less FXIII-A binding for both WT and Lys679Met 
FXIII-A when cells are incubated with BIO1211 (scale bars 10um). (b) Western blots show 
reduction in collagen I expression after incubation with 3 different integrin inhibitors (BIO1211, 
BOP, TCS2314), particularly for cells treated with Lys679Met FXIII-A compared to WT 
FXIII-A. (c) Graph shows reduced cell proliferation rates following FXIII-A treatment (WT or 
Lys679Met) compared to control after incubation with the 3 integrin inhibitors at 48 hours. (d) 
Western blot shows reduction of Collagen I expression after 48-hour treatment with 
ILDT235_238AAAA FXIII-A. (e) Graph shows reduced cell proliferation rate after site-
directed mutagenesis of ILDT motif of FXIII-A. These effects for (f) and (g) are common to 
the WT and Lys679Met FXIII-A but are more marked with Lys679Met FXIII-A. Experiments 
were performed in triplicate. The data show means +/- SD for three experiments*= p<0.05 vs 
control ** = p<0.01 vs control ***= p<0.001 vs control. C, W and M indicates control, wild 
type or mutant, respectively.
Figure 6:  WT and Lys679Met FXIII-A both increase Akt and ERK1/2 activation.  (a) 
NHDFs were treated with FXIII-A for 1, 4, or 8 hours with 2 nM PDGF-BB treatment as a 
positive control.  Activation levels of PDGFR and Akt were determined by immunoblotting 
with antibodies to Tyr (p)-751-PDGFRβ and Ser(p)-473-Akt1. All samples were normalized 
for equal amount with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). No activation 
was noted for p-PDGFR whereas both WT and Lys679Met FXIII-A showed transient increase 
in p-Akt signaling at 1 hour. (b) Activation level of LRP-6, ERK1/2 and p38α were determined 
by immunoblotting with antibodies to Ser (p)-1490-LRP6, Thr202 (p)/Thr204 (p)-
p44/42MAPK (ERK1/2) and Thr (p)-180)/Tyr (p)-182-p38α. All samples were normalized for 
equal amounts with GAPDH. Both WT and Lys679Met FXIII-A showed transient increase in 
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p-ERK1/2 signaling at 1 hour. (c) Phosphoproteins were quantified, averaged and expressed 
for NHDF cells treated with WT and Lys679Met FXIII-A as fold change over those of 
untreated cells. Both WT and Lys679Met FXIII-A showed similar ~two-fold increases in p-
Akt and p-ERK1/2 compared to control. Shown are the means +/- SD for three experiments. 
(d) A proposed schematic figure for FXIII-A and α4β1 integrins association on the cell surface 
and downstream signaling. Lys679Met may lead to a conformational change in the protein 
which promotes α4 integrin binding (right panel). WT and Lys679Met FXIII-A after 
association with integrins activate Akt and Erk1/2 resulting in cell proliferation, adhesion and 
collagen production. However, the enhanced action of mutant FXIII-A on α4 integrin could 
initiate different signaling cascades which still remain to be determined.
Page 39 of 59 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
 O
nly
 
Figure 1: Clinicopathologic and molecular basis of familial multiple dermatofibromas. (a)  Pedigrees of the 
two families showing all affected individuals with the F13A1 mutation c.2036A>T (Lys679Met). (b) Multiple 
dermatofibromas in Family 1 individual II-2 (left) and Family 2 individuals II-3 (right). (c) Histopathologic 
features of an excised dermatofibromas from an individual II-2 in Family 1 showing proliferation of fibro-
histiocytic cells within the dermis with an overlying Grenz zone (left image; hematoxylin and eosin, ×4; 
scale bar 500μm ). There is collagen entrapment at the periphery of the lesion as well as presence of 
hemosiderin pigment (right image; hematoxylin and eosin, ×10; scale bar 200μm).   
179x221mm (300 x 300 DPI) 
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Figure 2: Mutation Lys679Met in FXIII-A leads to reduced protein activity (a) S S P gel showing purity 
and levels of  T and Lys679Met FXIII-A purified recombinant proteins used in the assay. (b) Graph showing 
rate of pentylamine incorporation over time in preparations containing  W  Lys679Met mutant protein. (c) 
Percentage biotin incorporation as an estimation of FX activity. The data display mean 	
 SD for three 
experiments.  * *0007. (d) Cartoon representation of the inactive FXIII-A dimer (PD5 code 1F13). 
For one FXII-A molecule distinct structural regions are labeled and highlighted using different colors. The 
second FX-A molecule is shown in grey. Residue Lys679 is shown a s representation in 
Rd of the catalytic triad are shown in orange. Lys679 is locasd t Å away from the first ordered 
residue of the N
sinal activation peptide. (e) Cartoon representation of Ca2-activated FX
 monomer 
(PD5 code 4KTY) shown in the same orientation as in (d) Color-codes for the distinct structural regions are 
the same as in (d). The inhibitor bound in the active site is shown in cyan. Calcium ions are shown as grey 
spheres. Residue Lys679 is shown as stick representation in black. Ca2+-induced activation elicits a large 
swinging movement of the β-barre l domains. In this conformation Lys679 is located ~63 Å away from the 
active site. 
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Figure 3: Mutation Lys679Met in FIII-A leads to increased fibroblast proliferation, collagen production and 
changes in extracellular matrix organization. (a) Graph shows tha  proliferation is increased for 
Lys679Met F!!!"# compared to $% !!!"# at both 24 a&' () hours. (b) Collagen I western blot and (c) 
q+,- show that Lys679Met FXIII-A promotes more collagen I production after 4* hours compared to $%
FXIII-A. (d) Images of ,M produced by cells showing those treated with Lys679Met FXIII-A eDpress more 
collagen made of thickened fibers compared . $T FXIII-A (scale bar/ 02um). (e) Adhesion assay showing 
number of cells adhering to collagen I-coated plate at 0 3our is greater for Lys679Met FXIII-A compared to 
$% FXIII-A. The data indicate mea&/ 45" 6 for three eDperimen/7 8 9:2;2< 7 N 8 9:2;20 vs c.&=.>? NNN 
8 9:2;220 @s control. All eDperiments were done in triplicate A&8BC; C? $ and M indicates c.&=.>? DE>d type 
or muta&? respectively. 
0G)HI2)mm AB22 D B22 +!C
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Figure 4: Co-localization of α4, β1 and FJKKKLM on the cell surface suggeOQO TJKII-A binds to α4β1 integrin 
Immunofluorescence staining and confocal microscopy of fixed, permeabilized UVDFs on coverslips after 
treatment with YZ TJKKKLM or Lys679Met TJKKKLM for 2 hours before fixation. (a) Images show co-localization 
of active β1integrin and TJKKKLM after treatment with either YZ [\ mutant TJKKKLM (scale bars 10um). (b) 
Manders overlap co-efficient analysis showing percentage overlap between FJKKKLM and active β1integrin is 
greater for Lys679Met FJKKKLM] (c) Level of Active β1 integrin intensity per cell is greater for Lys679Met 
TJKKK-A.  (d) Images show co-localization of α4 integrin and TJKKKLM which is greater for Lys679Met TJKKKLM 
compared Q[ YZ TJKKKLM (scale bars 10um).  (e) Manders overlap co-efficient analysis showing percentage 
overlap between FJIII-A and integrin is greater for Lys679Met FJKKKLM] All experiments were done in 
triplicate. The data represent means +1- ^_ for three eDperimentsN ` pbe]ef vs control NN ` pbe]eg hs 
control NNN ` pbe]eeg hs control 
giijgklmm moee D oee _rKu
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Figure vw xyzzz{| associates with α4β1integrin via the ILDT motif in xyzzz{|. (a) }~DFs on coverslips were 
pre-treated with either DM ol) or z (฀4฀1 integrin inhibitor) for 2 hours and then /T FXIII-
Ax Lys679Met FXIII-A and control conditioned media was added f  hour. Confocal images show that 
z induces internalation of α4 integrin (small green  re is less FXIII-A binding for both /T 
and Lys679Met FXIII-A when cells are incubated with z (scale ba ). (b) /estern blots show 
reduction in collagen I eDpression after incubation with 3 different integrin inhibitors z 
4)x particularly for cells treated with Lys679Met FXIII-A compared to /T FXIII-A.  ph shows 
reduced cell proliferation rates following FXIII-A treatment (/T or Lys679Met) compared to control after 
incubation with the 3 integrin inhibitors at 4* hours. (d) /estern blot shows reduction of Collagen I 
eDpression after 4*-hour treatment with zv3*AAAA FXIII-A.  ph shows reduced cell 
proliferation rate after site-directed mutagenesis of z motif of FXIII-A. These effects for (f) and (g) are 
common to the /T and Lys679Met FXIII-A but are more marked with Lys679Met FXIII-A. βDperiments were 
performed in triplicate. The data show means +1-  for three eDperimentsN  ¡¢v vs control NN  
 ¡¢ vs control N££  ¡¢ vs control. Cx / and M indicates controlx wild type or mutantx respectively. 
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Figure 6: ¤¥ and Lys679Met ¦§¨¨¨©ª both increase A«¬ ­nd βRKP12 activation.  (a® ¯°±¦² were treated 
with FXIII-A for Px 4x or * hours with 2 n³ ´±µF©¶¶ treatment as a positive control.  Activation levels of 
´±µ¦· and Akt were determined by immunoblotting with antibodies to Tyr (p)-751-PDGFRβ a¸¹ ºer(p)-473-
AktP. All samples were normal»¼½¹ ¾or e0ual amount with glyceraldehyde-3-phosphate dehydrogenase 
¿µª´±°®À ¯Á activation was noted fÁÂ Ã©´±µFR whereas both /T and Lys679Met FXIII-A showed transient 
increase in p-Akt signaling at P hour. (b) Activation level of LR=-6x βRKP12 and p38α were determined by 
immunoblotting with antibodies ¬Á ºer (p)-PÄÆÇ©ÈR=6x Thr2ÇÉ (p)1ThrÉÇÄ (p)-p44142MA=K (βRKP12) and 
Thr (p)-PÊÇ®Ë¥ÌÂ (p)-182-p38α. All samples were norÍ­Î»¼ed for e0ual amounts with µA´±°À ¶oth /T and 
Lys679Met FXIII-A showed transient increase in p-βRKP12 signaling at P hour. (c) =hosphoproteins were 
0uantifiedx averaged and eDpressed fÁÂ ¯°±¦ cells treated with /T and Lys679Met FXIII-A as fold change 
over those of untreated celÎ²À ¶oth /T and Lys679Met FXIII-A showed similar ~two-fold increases in p-Akt 
and p-βRKP12 compared to con¬ÂÁÎÀ ºhown are the mea¸² ÏË© º± ¾or three eDperiments. (d) A proposed 
schematic figure for FXIII-A and α4β1 integrins association on the cell surface and downstream signaling. 
Lys679Met may lead to a conformational change in the protein which promotes α4 integrin binding (right 
panel). /T and Lys679Met FXIII-A after association with integrins activate Akt and βrkP12 resulting in cell 
proliferationx adhesion and collagen production. °ÁÐeverx the enhanced action of mutant FXIII-A on α4 
integrin could initiate different signaling cascades which still remain to be determined. 
P*ÑÒÑÓÑmm ¿ÔÇÇ D ÔÇÇ ±=I) 
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Supplementary information:
Coagulation Factor XIII-A Subunit Missense Mutation in the Pathobiology of Autosomal 
Dominant Multiple Dermatofibromas
Chavalit Supsrisunjai1,2, Chao-Kai Hsu1,3,4, Magdalene Michael5, Cédric Duval6, John Y. W. 
Lee1, Hsing-San Yang3, Hsin-Yu Huang7, Thitiwat Chaikul1, Alexandros Onoufriadis1, 
Roberto Steiner3, Robert A. S. Ariëns4, Ofer Sarig8, Eli Sprecher8,9, Marina Schwartz-Eskin8, 
Curt Samlaska10, Michael A. Simpson11, Eduardo Calonje1, 12, Maddy Parsons5*, John A. 
McGrath1*
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Table S1: A summary of the stepwise filtering approach to identify potentially shared variant 
within two pedigrees
Family 1 (Ukraine) Family 2 (USA) 
 Pedigrees I-2 II-2 III-1 II-1 II-3 II-2 III-2 II-5
Total variants 26063 26327 26278 26006 26072 26061 26236 25818
Variants with MAF<0.01 in 
1000 genomes, ESP, ExAC and 
6000 control exomes
1098 870 849 911 893 952 936 881
Heterozygous variants 768 850 833 872 866 918 910 852
Heterozygous nonsynonymous, 
splice-site, or insertion/deletion 
variants
556 541 526 530 496 578 808 530
Shared variants among affected 
individuals
118 113
Genes with variants that are 
shared between the two 
pedigrees 
1 (F13A1)
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Table S2: A summary of the statistics of exome sequencing and coverage
*CCDS: Consensus coding sequence
USA family Ukraine family
Case II-1 II-3 II-2 III-2 II-5 I-2 II-2 III-1
Total reads 75853390 80748322 55446430 86094748 68319976 92053964 103018007 106717428
Reads 
uniquely 
mapped to 
ÕÖ×
150 bp of 
the target 
sequence 41705779
(54.98%)
43183922
(53.48%)
30637737
(55.26%)
47083150
(54.69%)
35757820
(52.34%)
71957989
(78.17%)
80224711
(77.87%)
83043872
(77.82%)
Reads 
uniquely 
mapped to
target 
sequence 38934653
(51.33%)
40209995
(49.8%)
28501204
(51.4%)
43584762
(50.62%)
33379406
(48.86%)
65046797
(70.66%)
72451957
(70.33%)
74728981
(70.03%)
ØÙÚÛÜ
Coverage
(reads per 
position) 81.49 82.54 58.58 90.98 67.89 122.86 136.85 140.54
Target 
CCDS 
bases 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618
CCDS 
bases with 
coverage >
1x 33113976
(99.37%)
33109377
(99.36%)
33140600
(99.45%)
33147115
(99.47%)
33067174
(99.23%)
32979225
(98.97%)
33001727
(99.03%)
33003929
(99.04%)
CCDS 
bases with 
coverage >
5x
32754189
(98.29%)
32721647
(98.19%)
32734490
(98.23%)
32792592
(98.41%)
32528456
(97.61%)
32753490
(98.29%)
32795207
(98.41%)
32789252
(98.4%)
CCDS 
bases with 
coverage >
10x 32241535
(96.75%)
32181220
(96.57%)
31910596
(95.76%)
32289315
(96.9%)
31807387
(95.45%)
32513166
(97.57%)
32600284
(97.83%)
32581726
(97.77%)
CCDS 
bases with 
coverage >
20x 31106314
(93.35%)
31018109
(93.08%)
29043630
(87.16%)
31234256
(93.73%)
30095747
(90.31%)
31826135
(95.51%)
32059438
(96.21%)
32031001
(96.12%)
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Supplementary Methods and Results
F13A1 analysis in sporadic, non-familial dermatofibromas
We performed Sanger sequencing on 22 Taiwanese sporadic dermatofibroma samples and 28 
in-house sporadic dermatofibromas sample to determine whether Lys679Met variants and 
other potential variants are present in any sporadic dermatofibromas. We also hypothesized 
that variants in the promoter region of F13A1 might be associated with sporadic 
dermatofibroma. In order to determine single nucleotide polymorphisms (SNPs) in this area, 
Sanger sequencing was perf rmed on F13A1 gene and its promoter region. Regarding promoter 
region sequencing, we divided the promoter region (2400 bases) into 5 segments overlapping 
each other. The length of each segment is approximately 500 bases. Forward and reverse 
primers for each segment were designed by using an online tool (Primer 3) resulted in 5 pairs 
of primers (Supplementary table S6). A total of 50 sporadic dermatofibroma were sequenced 
for F13A1 gene and 22 DNA samples for promoter region. AmpliTaq Gold® 360 Master Mix 
(Thermofisher) and PCR protocol were used as previously described. The ABI 3730 DNA 
Sequencher (SeqGen, CA, USA) was then used for analyzing the sequence. The allele 
frequencies of each SNPs were compared with population databases, i.e. 1000 Genome Project 
and ExAC Browser, where available. For unreported SNPs, we compared with 30, in-house 
Taiwanese control samples. All 50 sporadic dermatofibroma were successfully sequenced for 
a further SNPs analysis. The total of 3 variants in F13A1 and 5 variants in promoter region 
were identified from Sanger sequencing (Supplementary table S3 and S4). None of these 
variants was statistically significant and different from the variants in the population database 
as compared by using Hardy-Weinberg equilibrium calculation and chi-square test (GraphPad 
Prism® version 8).
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Table S3: Hardy-Weinberg equilibrium and chi-square test for analysis of SNPs in F13A1 
from sporadic dermatofibromas 
Homozygous variant Heterozygous variant Wild typeÝÞßàÞáâ
Observed # Expected # Observed # Expected # Observed # Expected #
P value (two-
tailed)
rs5982
(c.1694C>T)
3 4.67 18 21.09 27 22.24 0.3561
rs5987
(c.1951G>A)
0 0.4 6 8.62 42 38.98 0.4889
rs5988 
(c.1954G>C)
0 0.41 7 8.69 41 38.89 0.6517
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Table S4: Hardy-Weinberg equilibrium and chi-square test for analysis of SNPs in F13A1 
promoter region from sporadic dermatofibromas
Homozygous variant Heterozygote Homozygous reference
ãäåæäçè
éêëìåíìî ï ðñòìóèìî ï éêëìåíìî ï ðñòìóèìî ï éêëìåíìî ï ðñòìóèìî ï
P value 
(two-
tailed)
rs1024231 
9 8.715 9 9.996 3 2.289 0.8481
rs2815822 
21 18.84 0 2.121 0 0.042 0.2995
rs1016925 
0 0.42 5 6.867 13.71 16 0.5197
rs1267856
0 2.06 8 8.84 12 9.1 0.2161
rs1267855 
2 2.74 7 9.44 11 7.82 0.3458
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Table S5 Primers for F13A1
Exon Forward Sequence
Tm 
ôõö÷
Reverse Sequence
øù ôõö÷
Exon 2 ACATGCCTTTTCTGTTGTCTTC 56.5 CTGGACCCAGAGTGGTG 57.6
Exon 3 CAACCCTTGTTTTTCTTGTTC 54.0 CAATGCAACCCATGGTGTC 56.7
Exon 4 GGCTTGTGAAATCAACCTAAC 55.9 GAAAACTAAATGTCTGCCTC 53.2
Exon 5 ACAGTCTGGTTTGGTAATAG 53.2 GACAATAACAAATTTTAAGTGG 50.9
Exon 6 AGAGAATATTTTGCTTGCAGAG 54.7 GGCAAATGACAGGTGTAACAG 57.9
Exon 7 CCTTCTCACTTCTCACGGAC 59.4 AAGAAATTACTCAGTTGGATAC 52.8
Exon 8 GTGATGTGTTTAGCTGTGGT 55.3 GATTGAGTCTATCTTGTGGT 53.2
Exon 9 GGGATTACAGGCATGAGCCAC 61.8 AGATCAGCAATGAAGCAAGTTCC 58.9
Exon 10 TGGACAGAATTGGGAGATGAC 57.9 TGTGTTAAGAGGTTGGGGAG 57.3
Exon 11 ATGATGGCTAATGCTCTCCT 55.3 TTCTCTGGAACTCATCTCTG 55.3
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Table S6 Primers for F13A1 promoter region (6: 6,319,201 – 6,321,384:-1; 2 KB upstream 
from start codon of F13A1)
Exon 12 CTGGTGGATTGTATTTTTGCC 55.9 ACAGCGAGTCTCACAAAGAAC 57.9
Exon 13 TGTGTGTGTTTTCTCCTACT 53.2 TTTGTCTCTGTTCCAGGATG 55.3
Exon 14 AGAGCAGAACGAGGTTTTATTTG 57.1 CACACAGAGAAAGCTTCCCAC 59.8
Exon 15 TCTTCCGAACCTCTCCTCTC 59.4 CCCTCTGCAGTCCTGTCTGG 63.5
Segment position Forward Tm 
(°C)      
Reverse Tm 
(°C)
1 6:6321519 
(-2678) – 
6320920 
(-2079)
GGCATGCACCTGTAGTTCC 59.1 AACCAGTTGCTGGGAGTACC 59.07
2 6:6321008 
(-2344) – 
6320456 
(-1792)
AAACCCTCCCAGACCCTCT 59.9 GCAAGTGGAGCTGCCTGT 60.1
3 6:6320531 
(-1867) – 
6319949 
(-1285)
ACCTCGGTTTCCTGGTTGA 60.5 TGAGAAATACCGAAGGTAGGC 58.3
4 6:6320031 
(-1367) – 
6319487 
(-823)
CCCCTTAGCACTGTGTCTCC 59.7 GCAGGCACTGAGCCAGTTTA 61.5
5 6:6319570 CCCTTCATTTGGTCATTTGG 60.2 TGCATGTGCTGTATCTATGTTCA 59.3
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Table S7 Primers for site directed mutagenesis
(-906) – 
6319039 
(-375)
Forward Tm 
(°C)      
Reverse Tm 
(°C)
Lys679
Met 
FXIIIA
CCA ATG AAG ATG ATG TCC CGT 
GAA ATC CGG CCC AAC TCC ACC 
GTG
69.5 CAC GGT GGA GTT GGG CCG GAT TTC ACG 
GGA CAT CAT CTT CAT TGG
67.0
FXIIIA 
with 
AAAA 
CTC TGT CCA TCA CAT ACA GGC 
AAG CGG CCG CGG CGC CAT 
CTT CAA ACT GAC CAT AGC T
93.5 AGC TAT GGT CAG TTT GAA GAT GGC 
GCC GCG GCC GCT TGC CTG TAT GTG 
ATG GAC AGA G
93.5
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Table S8 Primary and Secondary Antibodies
Antibody Product 
no.
Manufacturer Concentration Application 
Human Integrin alpha 4/CD49d MAb 
(Clone 7.2R)
MAB1354 bioTechne 1:100 IF
1:1000 WB 
IF, WB
Mouse monoclonal [12G10] to 
Integrin beta 1
NB100-
63255
bioTechne 1:100 IF IF
Rabbit polyclonal to FXIII-A ab97636 Abcam 1:1000 WB 
Sheep polyclonal to FXIII-A ab 104559 Abcam 1:100 IF 
Mouse monoclonal to Collagen I sc-293182 Santacruz 1:200 WB
Mouse monoclonal to Collagen I ab 90395 Abcam 1/2000 IF
Rabbit monoclonal [Y92] to PDGF 
Receptor beta
ab32570 Abcam 1:100 IF
1:5000 WB
IF, WB
Rabbit polyclonal to phosphor-
PDGF-Receptor β(Tyr751) 
3161 Cell 
Signaling 
Technology
1:1000 WB
Page 57 of 59 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
 O
nly
11
Polyclonal rabbit IgG to p38α AF8691 bioTechne 0.5µg/mL WB
Mouse monoclonal to human 
phospho-p38α
MAB8691 bioTechne 0.5µg/mL WB
Rabbit polyclonal antibody to Akt 9272 Cell 
Signaling 
Technology
1:1000 WB
Antibody Product 
no.
Manufacturer Concentration Application 
Rabbit polyclonal antibody to 
pAkt(Ser473)
9271 Cell 
Signaling 
Technology
1:1000 WB
Rabbit IgG antibody to LRP-6 2560 Cell 
Signaling 
Technology
1:1000 WB
Rabbit polyclonal to phosphor-
LRP6(Ser1490) antibody
2568 Cell 
Signaling 
Technology
1:1000 WB
Rabbit IgG antibody to p44/42 
MAPK(ERK1/2) antibody
4695 Cell 
Signaling 
Technology
1:1000 WB
Rabbit IgG antibody to phosphor-
p44/42 
MAPK(ERK1/2)(Thr202/Tyr204) 
antibody
4370 Cell 
Signaling 
Technology
1:1000 WB
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WB, western blot; IF, immunofluorescence; HRP, horseradish peroxidase
Rabbit polyclonal to fibronectin ab2413 Abcam 1:100 IF
1:1000 WB
IF, WB
Rabbit polyclonal to GAPDH ab9485 Abcam 1:2500 WB
Polyclonal Goat anti-rabbit Ig-HRP P0448 Dako 1: 5000 WB
Polyclonal Goat anti-mouse Ig-HRP P0447 Dako 1:2000 WB
Antibody Product 
no.
Manufacturer Concentration Application 
Mouse IgGκ binding protein-HRP sc-516102 Santacruz 1: 1000 WB
Donkey Anti-Rabbit IgG H&L 
(Alexa Fluor 647)
ab150075 Abcam 1:200 IF
Donkey Anti-Sheep IgG H&L (Alexa 
Fluor; 568)
ab150177 Abcam 1:200 IF
Goat Anti-Mouse IgG H&L (Alexa 
Fluor 488)
ab150113 Abcam 1:200 IF
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Supplementary Figures:
Figure S1. Chromatograms of F13A1 gene reveals the heterozygous variant c.2036A>T 
(Lys679Met) in all affected subjects.
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Figure S2. Haplotype analysis supports a common ancestral F13A1 mutant allele in 
families 1 and 2. (a, b) SNP genotyping of two individuals in two families and their relatives 
with four highly polymorphic markers within F13A1 shows that the individuals share the same 
haplogroup for the F13A1 containing c.2036A>T (indicated by black spot). Each color bar 
represents a distinct haplotype. 
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Figure S3: Levels of fibronectin and 4 integrin show no significant differences between 
treatments with either wild-type or mutant FXIII. (a, b) NHDFs were treated with FXIIIA 
for 48 hours with WT and Lys679Met FXIIIA; level of fibronectin was determined by 
immunoblotting with antibodies to Fibronectin. (c, d) NHDFs were treated with FXIIIA for 1, 
24, 48 hours with WT and Lys679Met FXIIIA; level of 4 integrin was determined by 
immunoblotting. All samples were normalized for equal amounts with GAPDH. (e) NHDFs 
were treated with FXIIIA for 4 and 48 hours; level of RhoA was determined by GTPase- 
enzyme linked immunoabsorbent assay (G-LISA) Activation assays protocol (Cytoskeleton, 
Denver, CO). Shown are the means +/- SD for three experiments.
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